GNPAT

glyceronephosphate O-acyltransferase

Basic information

Region (hg38): 1:231241207-231277973

Links

ENSG00000116906NCBI:8443OMIM:602744HGNC:4416Uniprot:O15228AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • rhizomelic chondrodysplasia punctata type 2 (Definitive), mode of inheritance: AR
  • rhizomelic chondrodysplasia punctata type 2 (Strong), mode of inheritance: AR
  • glyceronephosphate O-acyltransferase deficiency (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Rhizomelic chondrodysplasia punctata, type 2ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic1405476; 8466247; 7530787; 7541833; 9536089; 20583171; 21990100

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GNPAT gene.

  • not provided (19 variants)
  • Rhizomelic chondrodysplasia punctata type 2 (7 variants)
  • Rhizomelic chondrodysplasia punctata (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GNPAT gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
5
clinvar
121
clinvar
3
clinvar
129
missense
1
clinvar
1
clinvar
100
clinvar
4
clinvar
2
clinvar
108
nonsense
4
clinvar
12
clinvar
16
start loss
0
frameshift
14
clinvar
14
clinvar
28
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
9
clinvar
10
splice region
1
1
6
26
1
35
non coding
15
clinvar
114
clinvar
21
clinvar
150
Total 20 36 121 239 26

Highest pathogenic variant AF is 0.00000658

Variants in GNPAT

This is a list of pathogenic ClinVar variants found in the GNPAT region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-231241226-A-C Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 13, 2018)875921
1-231241232-G-C Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 13, 2018)296102
1-231241234-G-A Rhizomelic chondrodysplasia punctata type 2 Benign/Likely benign (Oct 21, 2018)296103
1-231241258-C-T Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 13, 2018)296104
1-231241295-C-T Rhizomelic chondrodysplasia punctata type 2 Benign/Likely benign (Jun 14, 2018)296105
1-231241297-G-T Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 13, 2018)876914
1-231241325-A-G Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 12, 2018)296106
1-231241332-C-A Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 13, 2018)296107
1-231241332-C-T not provided (-)625272
1-231241335-C-T Rhizomelic chondrodysplasia punctata type 2 • not specified Benign (Aug 10, 2021)296108
1-231241373-C-T Rhizomelic chondrodysplasia punctata type 2 Uncertain significance (Jan 12, 2018)296109
1-231241401-A-G Uncertain significance (Aug 07, 2021)1508398
1-231241401-ACT-A Rhizomelic chondrodysplasia punctata type 2 Likely pathogenic (Jul 03, 2023)2675931
1-231241404-C-T not specified • Rhizomelic chondrodysplasia punctata type 2 Benign (Jan 31, 2024)260361
1-231241408-T-C Likely benign (Dec 02, 2022)3014844
1-231241415-G-T Uncertain significance (Nov 03, 2021)1354439
1-231241420-C-G Likely benign (Aug 28, 2023)2916574
1-231241424-ACCAGTC-A Uncertain significance (Jan 02, 2021)1514054
1-231241434-G-C Uncertain significance (Aug 14, 2021)1382464
1-231241435-C-T Rhizomelic chondrodysplasia punctata type 2 Conflicting classifications of pathogenicity (Jan 22, 2024)296110
1-231241441-C-T Likely benign (Apr 28, 2023)2967280
1-231241443-T-C Rhizomelic chondrodysplasia punctata type 2 Conflicting classifications of pathogenicity (Jan 19, 2024)716279
1-231241444-G-A Likely benign (Sep 21, 2023)2902955
1-231241444-G-T Likely benign (Dec 15, 2022)2820904
1-231241447-C-T Likely benign (Sep 22, 2023)2805825

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GNPATprotein_codingprotein_codingENST00000366647 1636767
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.3040.6961257270211257480.0000835
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.6743163520.8990.00001874484
Missense in Polyphen89111.730.796561425
Synonymous-0.06371251241.010.000006341282
Loss of Function4.19834.60.2310.00000181434

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001810.000181
Ashkenazi Jewish0.00009920.0000992
East Asian0.00005440.0000544
Finnish0.00004650.0000462
European (Non-Finnish)0.00009680.0000967
Middle Eastern0.00005440.0000544
South Asian0.00009800.0000980
Other0.000.00

dbNSFP

Source: dbNSFP

Disease
DISEASE: Rhizomelic chondrodysplasia punctata 2 (RCDP2) [MIM:222765]: A form of rhizomelic chondrodysplasia punctata, a disease characterized by severely disturbed endochondral bone formation, rhizomelic shortening of femur and humerus, vertebral disorders, dwarfism, cataract, cutaneous lesions, facial dysmorphism, and severe mental retardation with spasticity. {ECO:0000269|PubMed:11152660, ECO:0000269|PubMed:21990100, ECO:0000269|PubMed:9536089}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Glycerophospholipid metabolism - Homo sapiens (human);Peroxisome - Homo sapiens (human);Plasmalogen Synthesis;Triacylglyceride Synthesis;Metabolism of lipids;Metabolism of proteins;Metabolism;Peroxisomal protein import;Glycerophospholipid metabolism;Glycerophospholipid biosynthesis;Phospholipid metabolism;Plasmalogen biosynthesis;Synthesis of PA (Consensus)

Recessive Scores

pRec
0.265

Intolerance Scores

loftool
0.328
rvis_EVS
-0.2
rvis_percentile_EVS
39.11

Haploinsufficiency Scores

pHI
0.521
hipred
N
hipred_score
0.426
ghis
0.553

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.977

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gnpat
Phenotype
endocrine/exocrine gland phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; pigmentation phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Gene ontology

Biological process
protein targeting to peroxisome;fatty acid metabolic process;phosphatidic acid biosynthetic process;synapse assembly;response to nutrient;ether lipid biosynthetic process;phospholipid biosynthetic process;cerebellum morphogenesis;paranodal junction assembly;response to drug;response to starvation;membrane organization;response to fatty acid
Cellular component
peroxisome;peroxisomal membrane;peroxisomal matrix;cytosol;membrane;mitochondrial membrane
Molecular function
signaling receptor binding;glycerone-phosphate O-acyltransferase activity;palmitoyl-CoA hydrolase activity